FLGT (Fulgent Genetics) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Fulgent Genetics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

Fulgent Genetics's long-term debt to total assets ratio declined from Dec. 2023 (0.01) to Dec. 2024 (0.01). It may suggest that Fulgent Genetics is progressively becoming less dependent on debt to grow their business.

Fulgent Genetics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Fulgent Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics LT-Debt-to-Total-Asset Chart

Fulgent Genetics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Fulgent Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Fulgent Genetics LT-Debt-to-Total-Asset Calculation

Fulgent Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	6.613	/	1219.964
	=	0.01

Fulgent Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	6.613	/	1219.964
	=	0.01

Fulgent Genetics (NAS:FLGT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Fulgent Genetics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

FLGT:Mexico 7F0:Germany

Address

4399 Santa Anita Avenue, El Monte, CA, USA, 91731

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Executives

Paul Kim	officer: CFO and Treasurer	4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao	10 percent owner, officer: Chief Scientific Officer	4399 SANTA ANITA AVE., EL MONTE CA 91731
Jian Xie	officer: Chief Operating Officer	C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Ming Hsieh	director, 10 percent owner, officer: President and CEO	4399 SANTA ANITA AVE., EL MONTE CA 91731
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post	director
Michael Nohaile	director	C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger	director	4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust	10 percent owner	4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh	director	100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Fulgent Genetics, Inc.	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay	director	6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc.	10 percent owner	#6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663